Celgene's arthritis drug fails to meet expectations for additional use

July 9, 2014 2:37 PM

17 0

Shares of Celgene slipped in premarket trading today after the Summit-based drugmaker said its psoriatic arthritis treatment Otezla missed the main goal of a late-stage study exploring an additional use.

The company said Otezla did not achieve a statistically significant improvement when compared to a placebo in a study of patients with a painful spinal joint disorder called ankylosing spondylitis. But the drug did show signs of effectiveness in patients with early stages of the disease who took Ote...

Read more

To category page